title: Use of anti-GP IIb-IIIa in acute thrombosis after intracoronary stent implantation.
abstract: Acute occlusion of coronary stents still occurs in 0.5-2% of patients. The usefulness of GP IIb-IIIa receptor inhibitors has never been evaluated in this indication. After 1,454 stent implantations, acute occlusion occurred in 16 patients. Direct percutaneous transluminal coronary angioplasty (PTCA) was immediately performed. In eight patients, no recurrent thrombosis occurred during the 15 min following PTCA, and abciximab infusion was started after this period. In six patients, immediate recurrent thrombosis occurred in the stent. In these cases, an intravenous bolus of abciximab followed by a new inflation at low pressure was performed. Fifteen min after the bolus, stable TIMI 3 flow was restored in all six cases, and no thrombus or haziness remained. In two patients, a TIMI 0 flow persisted despite PTCA and the use of a bolus of abciximab. No recurrent ischemic symptoms were observed before hospital discharge. Abciximab in combination with balloon angioplasty can be used safely to control acute thrombosis after stent deployment.
authors.affiliation: Department of Cardiology, Hôpital Broussais, Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Henry
authors.forename: K
authors.initials: K
authors.lastname: Boughalem
authors.forename: J P
authors.initials: JP
authors.lastname: Rinaldi
authors.forename: S
authors.initials: S
authors.lastname: Makowski
authors.forename: K
authors.initials: K
authors.lastname: Khalife
authors.forename: J L
authors.initials: JL
authors.lastname: Guermonprez
authors.forename: D
authors.initials: D
authors.lastname: Blanchard
mesh_terms: D000077284:Abciximab; D000208:Acute Disease; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003328:Coronary Thrombosis / Q000209:etiology / Q000628:therapy*; D003331:Coronary Vessels; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D012008:Recurrence; D015607:Stents / Q000009:adverse effects*
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab